<p>Recent studies have demonstrated that for various diseases, incorporating polygenic risk scores (PRSs) for other traits and diseases into the PRS-based risk prediction model may improve predictive performance – known as Multiple Polygenic Score (MPS) approach. We aimed to examine whether the MPS approach improves colorectal cancer (CRC) risk prediction. We included 2,187 non-CRC PRSs from the polygenic Score (PGS) Catalog and used machine learning (ML) models to select the most predictive non-CRC PRSs, utilizing individual-level data from 31,257 CRC cases and 33,408 controls. An independent dataset from the Genetic Epidemiology Research in Adult Health and Aging (GERA) cohort (4,852 cases and 67,939 controls) was randomly split into subsets for model estimation and validation. The model combined MPS with two existing CRC-PRSs based on known loci and genome-wide genotyping. We then assessed model performance by calculating the area under the receiver operating curve (AUC) in the validation set and performed 1,000 bootstrapped iterations to evaluate AUC improvements. The ML model selected 337 non-CRC PRSs predictive of CRC risk. Adding MPS to the CRC-PRSs significantly improved AUC by 0.017 (95% CI: 0.011–0.022, <i>p</i> &lt; 0.0001) when combined with known-loci CRC-PRS, 0.005 (95% CI: 0.002–0.007, <i>p</i> = 0.0005) with genome-wide CRC-PRS, and 0.004 (95% CI: 0.002–0.006, <i>p</i> = 0.0005) with both the known loci and genome-wide CRC-PRSs. These findings demonstrate MPS’s potential to refine CRC risk prediction models and highlight opportunities for further advancements in risk prediction.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Multiple polygenic score approach in colorectal cancer risk prediction

  • Shangqing Joyce Jiang,
  • Minta Thomas,
  • Elisabeth A. Rosenthal,
  • Amanda I. Phipps,
  • Lori C. Sakoda,
  • Franzel J. B. van Duijnhoven,
  • Andrew J. Pellatt,
  • Christy L. Avery,
  • Sonja I. Berndt,
  • D. Timothy Bishop,
  • Sergi Castellví-Bel,
  • Andrew T. Chan,
  • Robert C. Grant,
  • Chris Gignoux,
  • Andrea Gsur,
  • Marc J. Gunter,
  • Christopher A. Haiman,
  • Michael Hoffmeister,
  • Gail P. Jarvik,
  • Mark A. Jenkins,
  • Temitope O. Keku,
  • Sébastien Küry,
  • Jeffrey K. Lee,
  • Loic Le Marchand,
  • Victor Moreno,
  • Polly A. Newcomb,
  • Christina C. Newton,
  • Shuji Ogino,
  • Julie R. Palmer,
  • Rachel Pearlman,
  • Conghui Qu,
  • Robert E. Schoen,
  • Caroline Y. Um,
  • Bethany Van Guelpen,
  • Kala Visvanathan,
  • Veronika Vymetalkova,
  • Emily White,
  • Michael O. Woods,
  • Elizabeth A. Platz,
  • Hermann Brenner,
  • Douglas A. Corley,
  • Iris Landorp Vogelaar,
  • Li Hsu,
  • Ulrike Peters

摘要

Recent studies have demonstrated that for various diseases, incorporating polygenic risk scores (PRSs) for other traits and diseases into the PRS-based risk prediction model may improve predictive performance – known as Multiple Polygenic Score (MPS) approach. We aimed to examine whether the MPS approach improves colorectal cancer (CRC) risk prediction. We included 2,187 non-CRC PRSs from the polygenic Score (PGS) Catalog and used machine learning (ML) models to select the most predictive non-CRC PRSs, utilizing individual-level data from 31,257 CRC cases and 33,408 controls. An independent dataset from the Genetic Epidemiology Research in Adult Health and Aging (GERA) cohort (4,852 cases and 67,939 controls) was randomly split into subsets for model estimation and validation. The model combined MPS with two existing CRC-PRSs based on known loci and genome-wide genotyping. We then assessed model performance by calculating the area under the receiver operating curve (AUC) in the validation set and performed 1,000 bootstrapped iterations to evaluate AUC improvements. The ML model selected 337 non-CRC PRSs predictive of CRC risk. Adding MPS to the CRC-PRSs significantly improved AUC by 0.017 (95% CI: 0.011–0.022, p < 0.0001) when combined with known-loci CRC-PRS, 0.005 (95% CI: 0.002–0.007, p = 0.0005) with genome-wide CRC-PRS, and 0.004 (95% CI: 0.002–0.006, p = 0.0005) with both the known loci and genome-wide CRC-PRSs. These findings demonstrate MPS’s potential to refine CRC risk prediction models and highlight opportunities for further advancements in risk prediction.